CD19 and systemic lupus erythematosus: Thus, the anti–PD-1 CAR could be used to reset the immune repertoire in a similar manner, as has been recently described with the anti-CD19 CAR to deplete CD19+ plasmablasts in refractory SLE (61, 62) and in a patient with antisynthase syndrome (63).